Remyelination and multiple sclerosis

therapeutic approaches and challenges

Meredith D. Hartley, Ghadah Altowaijri, Dennis Bourdette

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system. After acute inflammatory mediated demyelination, some remyelination often occurs, but in chronic demyelinated MS plaques, remyelination frequently fails. Chronically demyelinated axons cause a variety of symptoms and probably are more likely to degenerate, leading to irreversible clinical disability. Oligodendrocyte precursor cells (OPCs) present in the adult brain can proliferate and differentiate to remyelinate lesions. Failure of remyelination in the majority of MS patients is secondary to arrest in OPC differentiation. Many therapies have been developed to modulate the immune response in MS, but no neuroprotective or remyelinating therapies are available. Promoting remyelination is a promising avenue for protecting axons, reversing neurologic disability and preventing progressive disease in MS. This review will begin with an overview of remyelination and remyelination failure, consequences of demyelination, and available animal disease models. In addition, preclinical and clinical studies on the most promising potential therapies for inducing remyelination will be described.

Original languageEnglish (US)
Pages (from-to)485
Number of pages1
JournalCurrent Neurology and Neuroscience Reports
Volume14
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

Multiple Sclerosis
Demyelinating Diseases
Oligodendroglia
Axons
Therapeutics
Animal Disease Models
Nervous System
Cell Differentiation
Central Nervous System
Brain

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Remyelination and multiple sclerosis : therapeutic approaches and challenges. / Hartley, Meredith D.; Altowaijri, Ghadah; Bourdette, Dennis.

In: Current Neurology and Neuroscience Reports, Vol. 14, No. 10, 01.10.2014, p. 485.

Research output: Contribution to journalArticle

@article{f0a0dfab602749f7942ac85c5c534315,
title = "Remyelination and multiple sclerosis: therapeutic approaches and challenges",
abstract = "Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system. After acute inflammatory mediated demyelination, some remyelination often occurs, but in chronic demyelinated MS plaques, remyelination frequently fails. Chronically demyelinated axons cause a variety of symptoms and probably are more likely to degenerate, leading to irreversible clinical disability. Oligodendrocyte precursor cells (OPCs) present in the adult brain can proliferate and differentiate to remyelinate lesions. Failure of remyelination in the majority of MS patients is secondary to arrest in OPC differentiation. Many therapies have been developed to modulate the immune response in MS, but no neuroprotective or remyelinating therapies are available. Promoting remyelination is a promising avenue for protecting axons, reversing neurologic disability and preventing progressive disease in MS. This review will begin with an overview of remyelination and remyelination failure, consequences of demyelination, and available animal disease models. In addition, preclinical and clinical studies on the most promising potential therapies for inducing remyelination will be described.",
author = "Hartley, {Meredith D.} and Ghadah Altowaijri and Dennis Bourdette",
year = "2014",
month = "10",
day = "1",
doi = "10.1007/s11910-014-0485-1",
language = "English (US)",
volume = "14",
pages = "485",
journal = "Current Neurology and Neuroscience Reports",
issn = "1528-4042",
publisher = "Current Medicine Group",
number = "10",

}

TY - JOUR

T1 - Remyelination and multiple sclerosis

T2 - therapeutic approaches and challenges

AU - Hartley, Meredith D.

AU - Altowaijri, Ghadah

AU - Bourdette, Dennis

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system. After acute inflammatory mediated demyelination, some remyelination often occurs, but in chronic demyelinated MS plaques, remyelination frequently fails. Chronically demyelinated axons cause a variety of symptoms and probably are more likely to degenerate, leading to irreversible clinical disability. Oligodendrocyte precursor cells (OPCs) present in the adult brain can proliferate and differentiate to remyelinate lesions. Failure of remyelination in the majority of MS patients is secondary to arrest in OPC differentiation. Many therapies have been developed to modulate the immune response in MS, but no neuroprotective or remyelinating therapies are available. Promoting remyelination is a promising avenue for protecting axons, reversing neurologic disability and preventing progressive disease in MS. This review will begin with an overview of remyelination and remyelination failure, consequences of demyelination, and available animal disease models. In addition, preclinical and clinical studies on the most promising potential therapies for inducing remyelination will be described.

AB - Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system. After acute inflammatory mediated demyelination, some remyelination often occurs, but in chronic demyelinated MS plaques, remyelination frequently fails. Chronically demyelinated axons cause a variety of symptoms and probably are more likely to degenerate, leading to irreversible clinical disability. Oligodendrocyte precursor cells (OPCs) present in the adult brain can proliferate and differentiate to remyelinate lesions. Failure of remyelination in the majority of MS patients is secondary to arrest in OPC differentiation. Many therapies have been developed to modulate the immune response in MS, but no neuroprotective or remyelinating therapies are available. Promoting remyelination is a promising avenue for protecting axons, reversing neurologic disability and preventing progressive disease in MS. This review will begin with an overview of remyelination and remyelination failure, consequences of demyelination, and available animal disease models. In addition, preclinical and clinical studies on the most promising potential therapies for inducing remyelination will be described.

UR - http://www.scopus.com/inward/record.url?scp=84927170176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927170176&partnerID=8YFLogxK

U2 - 10.1007/s11910-014-0485-1

DO - 10.1007/s11910-014-0485-1

M3 - Article

VL - 14

SP - 485

JO - Current Neurology and Neuroscience Reports

JF - Current Neurology and Neuroscience Reports

SN - 1528-4042

IS - 10

ER -